Disability Changes in the Absence of Relapse in the Phase 3 ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis By admin / 10/26/2022
Ublituximab Treatment Is Associated With a Significant Proportion of Participants Achieving NEDA-4 By admin / 10/26/2022
Disease Outcomes With Ublituximab in Treatment-Naive Participants: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 10/26/2022
B-Cell Depletion and Return in Participant Subgroups of the Phase 3 ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis By admin / 10/26/2022
Ublituximab Is Associated With Significant Improvement in the Multiple Sclerosis Functional Composite (MSFC): Results From the Phase 3 ULTIMATE I & II Studies By admin / 10/14/2021
Phase 3 Results of the ULTIMATE I & II Global Studies: Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis By admin / 10/14/2021
Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS) By admin / 09/12/2019
Study Design and Patient Demographics of the ULTIMATE Phase III Trials Evaluating Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS) By admin / 09/12/2019
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) By admin / 10/11/2018
Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets By admin / 10/27/2017
